NEW YORK (GenomeWeb News) – Almac Diagnostics said today that it will collaborate with Lilly UK to develop a companion diagnostic for a combination lung cancer therapy.
The companies will evaluate a predictive marker for a drug combination used in treating non-squamous, non-small cell lung cancer patients. Specifically, they will study Thymidylate Synthase as a marker for response to the Eli Lilly drug pemetrexid (Alimta) in combination with cisplatin.
They also will study "alternative strategies" for developing other markers for the same combination therapy. The alternative studies will involve using global gene expression profiling from formalin-fixed paraffin-embedded tumor samples using Almac's Lung Cancer DSA microarray.
Almac said it will conduct global gene expression profiling, microRNA profiling, SNP genotyping, qPCR validation, and data analysis to develop the companion diagnostic.